LR-90

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

LR-90还用于糖尿病动物模型的研究。LR-90是一种高级糖基化终末产物(AGE)抑制剂，抑制人单核细胞的炎症反应。

LR-90 is also used in the research of diabetic animal model.LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes.?(In Vitro):LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours.?LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells.LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours.(In Vivo):LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation.LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats.

LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours.LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours.LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells. Cell Viability Assay Cell Line:THP-1 cells Concentration:0, 25, 50, 100, and 200 μM Incubation Time:24 hours Result:Showed no cytotoxicity to THP-1 cells.RT-PCR Cell Line:THP-1 cells Concentration:0, 25, 50, 100, and 200 μM Incubation Time:One hour before S100b addition for 4 hours Result:Dose-dependently inhibited mRNA expression of RAGE, MCP-1, COX-2, IP-10, and NOX2 stimulated with S100b.

LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats.LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation. Animal Model:Male ZDF rats (13 to 40 weeks)Dosage:50 mg/L Administration:P.O. for 27 weeks Result:Significantly reduced plasma triacylglycerol and cholesterol by ～55% and ～30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight.

——

Others

Other Targets

BRD4

——

——

245075-84-7

709.58

C35H34Cl2N4O8

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (140.93 mM)

CC(C)(Oc1ccc(NC(=O)Nc2ccc(Cc3ccc(NC(=O)Nc4ccc(OC(C)(C)C(O)=O)cc4)c(Cl)c3)cc2Cl)cc1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years